Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Neuroprotective Drugs Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Cholinesterase inhibitors
  • 1.3.3 Anti-inflammatory
  • 1.3.4 Others
• 1.4 Market Segment by Application
  • 1.4.1 Global Neuroprotective Drugs Market Share by Application (2019-2025)
  • 1.4.2 Alzheimer's disease
  • 1.4.3 Parkinson's disease
  • 1.4.4 Others
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Neuroprotective Drugs Market Size
  • 2.1.1 Global Neuroprotective Drugs Revenue 2014-2025
  • 2.1.2 Global Neuroprotective Drugs Sales 2014-2025
• 2.2 Neuroprotective Drugs Growth Rate by Regions
  • 2.2.1 Global Neuroprotective Drugs Sales by Regions 2014-2019
  • 2.2.2 Global Neuroprotective Drugs Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Neuroprotective Drugs Sales by Manufacturers
  • 3.1.1 Neuroprotective Drugs Sales by Manufacturers 2014-2019
  • 3.1.2 Neuroprotective Drugs Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Neuroprotective Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Neuroprotective Drugs Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Neuroprotective Drugs Market Concentration Ratio (CR5 and HHI)
• 3.3 Neuroprotective Drugs Price by Manufacturers
• 3.4 Key Manufacturers Neuroprotective Drugs Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Neuroprotective Drugs Market
• 3.6 Key Manufacturers Neuroprotective Drugs Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Cholinesterase inhibitors Sales and Revenue (2014-2019)
  • 4.1.2 Anti-inflammatory Sales and Revenue (2014-2019)
  • 4.1.3 Others Sales and Revenue (2014-2019)
• 4.2 Global Neuroprotective Drugs Sales Market Share by Type
• 4.3 Global Neuroprotective Drugs Revenue Market Share by Type
• 4.4 Neuroprotective Drugs Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Neuroprotective Drugs Sales by Application

6 United States

• 6.1 United States Neuroprotective Drugs Breakdown Data by Company
• 6.2 United States Neuroprotective Drugs Breakdown Data by Type
• 6.3 United States Neuroprotective Drugs Breakdown Data by Application

7 European Union

• 7.1 European Union Neuroprotective Drugs Breakdown Data by Company
• 7.2 European Union Neuroprotective Drugs Breakdown Data by Type
• 7.3 European Union Neuroprotective Drugs Breakdown Data by Application

8 China

• 8.1 China Neuroprotective Drugs Breakdown Data by Company
• 8.2 China Neuroprotective Drugs Breakdown Data by Type
• 8.3 China Neuroprotective Drugs Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Neuroprotective Drugs Breakdown Data by Company
• 9.2 Rest of World Neuroprotective Drugs Breakdown Data by Type
• 9.3 Rest of World Neuroprotective Drugs Breakdown Data by Application
• 9.4 Rest of World Neuroprotective Drugs Breakdown Data by Countries
  • 9.4.1 Rest of World Neuroprotective Drugs Sales by Countries
  • 9.4.2 Rest of World Neuroprotective Drugs Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Genervon Biopharmaceuticals (Canada)
  • 10.1.1 Genervon Biopharmaceuticals (Canada) Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Neuroprotective Drugs
  • 10.1.4 Neuroprotective Drugs Product Introduction
  • 10.1.5 Genervon Biopharmaceuticals (Canada) Recent Development
• 10.2 NeuroVive Pharmaceutical (Sweden)
  • 10.2.1 NeuroVive Pharmaceutical (Sweden) Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Neuroprotective Drugs
  • 10.2.4 Neuroprotective Drugs Product Introduction
  • 10.2.5 NeuroVive Pharmaceutical (Sweden) Recent Development
• 10.3 Ceregene (USA)
  • 10.3.1 Ceregene (USA) Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Neuroprotective Drugs
  • 10.3.4 Neuroprotective Drugs Product Introduction
  • 10.3.5 Ceregene (USA) Recent Development
• 10.4 BHRPharma (Thailand)
  • 10.4.1 BHRPharma (Thailand) Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Neuroprotective Drugs
  • 10.4.4 Neuroprotective Drugs Product Introduction
  • 10.4.5 BHRPharma (Thailand) Recent Development
• 10.5 Neuren Pharmaceuticals (Australia)
  • 10.5.1 Neuren Pharmaceuticals (Australia) Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Neuroprotective Drugs
  • 10.5.4 Neuroprotective Drugs Product Introduction
  • 10.5.5 Neuren Pharmaceuticals (Australia) Recent Development
• 10.6 Allon therapeutics (Canada)
  • 10.6.1 Allon therapeutics (Canada) Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Neuroprotective Drugs
  • 10.6.4 Neuroprotective Drugs Product Introduction
  • 10.6.5 Allon therapeutics (Canada) Recent Development
• 10.7 Bionure Inc. (USA)
  • 10.7.1 Bionure Inc. (USA) Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Neuroprotective Drugs
  • 10.7.4 Neuroprotective Drugs Product Introduction
  • 10.7.5 Bionure Inc. (USA) Recent Development

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Neuroprotective Drugs Sales Channels
  • 11.2.2 Neuroprotective Drugs Distributors
• 11.3 Neuroprotective Drugs Customers

12 Market Forecast

• 12.1 Global Neuroprotective Drugs Sales and Revenue Forecast 2019-2025
• 12.2 Global Neuroprotective Drugs Sales Forecast by Type
• 12.3 Global Neuroprotective Drugs Sales Forecast by Application
• 12.4 Neuroprotective Drugs Forecast by Regions
  • 12.4.1 Global Neuroprotective Drugs Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Neuroprotective Drugs Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

Neuroprotective Drugs consist of medications that can be used to protect or preserve the neuronal cells of the brain from degeneration, stress, and injury, which can impair cognitive functions. 
In 2019, the market size of Neuroprotective Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Neuroprotective Drugs.

This report studies the global market size of Neuroprotective Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Neuroprotective Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Genervon Biopharmaceuticals (Canada)
NeuroVive Pharmaceutical (Sweden)
Ceregene (USA)
BHRPharma (Thailand)
Neuren Pharmaceuticals (Australia)
Allon therapeutics (Canada)
Bionure Inc. (USA)
...

Market Segment by Product Type
Cholinesterase inhibitors
Anti-inflammatory
Others

Market Segment by Application
Alzheimer's disease
Parkinson's disease
Others

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Neuroprotective Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Neuroprotective Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Neuroprotective Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025